VISEN PHARMA-B (02561) released a monthly return for the period ending 28 February 2026, confirming that its authorized share capital stood at 500.00 million ordinary shares, each with a par value of USD 0.0001, totaling USD 50,000. The number of issued shares remained at 113.93 million, with no reported treasury shares.

The applicable public float threshold is 25%, and no non-compliance was reported. No new shares were issued under the Post-IPO Share Award Scheme or other arrangements, and no reduction or cancellation of shares took place. All necessary confirmations were provided in accordance with relevant regulatory requirements.